Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | DDX3X | O00571 | 4/20 | 0.34 |
| ▸ | MIF | P14174 | 3/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22358510 | 0.93 | KDM4C (0.42) | KDM4CNPC1RAB9AL3MBTL1SPHK1 | |
| SCHEMBL27398359 | 0.88 | KDM4C (0.39) | KDM4CNPC1RAB9AL3MBTL1SPHK1 | |
| SCHEMBL22358511 | 0.88 | KDM4C (0.43) | KDM4CNPC1RAB9AL3MBTL1SPHK1 | |
| SCHEMBL22859609 | 0.86 | KDM4C (0.44) | KDM4CNPC1RAB9AL3MBTL1SPHK1 | |
| SCHEMBL18818594 | 0.84 | RXRA (0.40) | MIFRXRAGRIN1GRIN2B | |
| SCHEMBL20857077 | 0.82 | KDM4C (0.46) | KDM4CNPC1RAB9AL3MBTL1MIF | |
| SCHEMBL28433534 | 0.82 | KDM4C (0.46) | KDM4CNPC1RAB9AL3MBTL1DDX3X | |
| SCHEMBL20118087 | 0.82 | RXRA (0.39) | MIFRXRAGRIN1GRIN2B | |
| SCHEMBL20857100 | 0.81 | SPHK1 (0.42) | KDM4CNPC1RAB9AL3MBTL1SPHK1 | |
| SCHEMBL22859650 | 0.78 | RXRA (0.37) | SPHK1MIFRXRAGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230003706-A1 | METHODS OF EVALUATING SMALL MOLECULE-MODIFIED POLYMERS IN COMPOSITIONS | SIGILON THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230003706-A1 | METHODS OF EVALUATING SMALL MOLECULE-MODIFIED POLYMERS IN COMPOSITIONS | FN1, MFAP1, FIBP | KDM4C 1766/4885NPC1 2000/4885RAB9A 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.